RTP Mobile Logo
Lung Cancer Update for Nurses, Issue 1, 2009
Released September 2009

Featuring interviews with Alan B Sandler, MD and Beth Eaby, MSN, CRNP, OCN. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Lung cancer is the leading cause of cancer mortality in the United States for both men and women. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85 percent of patients who develop lung cancer will die from it. Published results from clinical trials lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care, oncology nurses must be well informed of these advances. Lung Cancer Update for Nurses provides an overview of the latest research developments and up-to-date clinical management strategies in lung cancer paired with the opinions of a nurse practitioner and clinical investigator experienced in the treatment of lung cancer.

    PURPOSE STATEMENT

    To present the most current research developments in lung cancer and to provide the perspectives of a nurse practitioner and clinical investigator on the diagnosis and treatment of lung cancer.

    EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF LUNG CANCER UPDATE FOR NURSES

    • Apply the results of emerging research with novel chemotherapies and regimens to the management of non-small cell lung cancer (NSCLC).
    • Offer best-practice supportive management strategies to address side effects and toxicities associated with the systemic treatment of NSCLC.
    • Effectively utilize tumor histology and biomarkers in making evidence-based lung cancer treatment decisions.
    • Counsel appropriate patients about the benefits and risks of monoclonal antibodies targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) in the treatment of NSCLC.
    • Educate patients with EGFR-mutated NSCLC about the individualized clinical utility of tyrosine kinase inhibitors targeting this growth pathway.
    • Recognize the psychosocial and emotional needs of caregivers, patients and their loved ones associated with the diagnosis and treatment of lung cancer.
    ACCREDITATION STATEMENTS

    Research To Practice is an approved provider of continuing nursing education by NJSNA, an accredited approver, by the American Nurses Credentialing Center’s Commission on Accreditation.

    There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
     
    This activity for 1.6 contact hours is provided by Research To Practice. Provider Number: P215-1/10-8/10.

    CME credit is no longer available for this issue

    HOW TO USE THIS CNE ACTIVITY

    CME credit is no longer available for this issue

    This is an audio CNE activity. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.

    Participants should read the learning objectives and faculty disclosures and listen to the audio program.

    CONTENT VALIDATION AND DISCLOSURES


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SandlerConsulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, ImClone Systems Incorporated, Novartis Pharmaceuticals Corporation, OSI Oncology, Pfizer Inc, Pharmion Corporation, Roche Laboratories Inc, Sanofi-Aventis, Schering-Plough Corporation, Wyeth; Speakers Bureau: Abraxis BioScience, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis. Ms EabySpeakers Bureau: Genentech BioOncology, Merck and Company Inc, Sanofi-Aventis.

    EDITOR
    Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, Eli Lilly and Company, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Wyeth.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.


    This program is supported by an educational grant from Genentech BioOncology & OSI Oncology.


    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review/release date:
    September 2009
    Expiration date: September 2010

Acknowledge and close

Lung Cancer Update for Nurses, Issue 1, 2009
Released September 2009

Featuring interviews with Alan B Sandler, MD and Beth Eaby, MSN, CRNP, OCN. (Audio Content)